The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
Open accessAbstract
BACKGROUND: Antiretroviral preexposure prophylaxis has been shown to reduce the risk of human immunodeficiency virus type 1 (HIV-1) infection in some studies, but conflicting results have been reported among studies, probably due to challenges of adherence to a daily regimen. METHODS: We conducted a double-blind, randomized trial of antiretroviral therapy for preexposure HIV-1 prophylaxis among men who have unprotected anal sex with men. Participants were randomly assigned to take a combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) or placebo before and after sexual activity. All participants received risk-reduction counseling and condoms and were regularly tested for HIV-1 and HIV-2 and other sexually transmitted infections. RESULTS: Of the 414 participants who underwent randomization, 400 who did not have HIV infection were enrolled (199 in the TDF-FTC group and 201 in the placebo group). All participants were followed for a median of 9.3 months (interquartile range, 4.9 to 20.6). A total of 16 HIV-1 infections occurred during follow-up, 2 in the TDF-FTC group (incidence, 0.91 per 100 person-years) and 14 in the placebo group (incidence, 6.60 per 100 person-years), a relative reduction in the TDF-FTC group of 86% (95% confidence interval, 40 to 98; P=0.002). Participants took a median of 15 pills of TDF-FTC or placebo per month (P=0.57). The rates of serious adverse events were similar in the two study groups. In the TDF-FTC group, as compared with the placebo group, there were higher rates of gastrointestinal adverse events (14% vs. 5%, P=0.002) and renal adverse events (18% vs. 10%, P=0.03). CONCLUSIONS: The use of TDF-FTC before and after sexual activity provided protection against HIV-1 infection in men who have sex with men. The treatment was associated with increased rates of gastrointestinal and renal adverse events. (Funded by the National Agency of Research on AIDS and Viral Hepatitis [ANRS] and others; ClinicalTrials.gov number, NCT01473472.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of HIV-1 infection with early antiretroviral therapy.
Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105243 · Cited by 6,873
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Self-citationConnor, E. M., Sperling, R. S., Gelber, R., Kiselev, P., Scott, G., O'Sullivan, M. J., VanDyke, R., Bey, M., Shearer, W., Jacobson, R. L., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411033311801 · Cited by 3,705
Self-citationAntiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Auvert, B., Taljaard, D., Lagarde, E., Sobngwi-Tambekou, J., Sitta, R., & Puren, A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020298 · Cited by 2,451
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
McCormack, S., Dunn, D. T., Desai, M., Dolling, D. I., Gafos, M., Gilson, R., Sullivan, A. K., Clarke, A., Reeves, I., Schembri, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00056-2 · Cited by 1,878
Self-citationConnor, E. M., Sperling, R. S., Gelber, R., Kiselev, P., Scott, G., O'Sullivan, M. J., VanDyke, R., Bey, M., Shearer, W., Jacobson, R. L., et al. (1995) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199504000-00002 · Cited by 1,816
Self-citationPreexposure Prophylaxis for HIV Infection among African Women
Van Damme, L., Corneli, A., Ahmed, K., Agot, K., Lombaard, J., Kapiga, S., Malahleha, M., Owino, F., Manongi, R., Onyango, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202614 · Cited by 1,603
Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., Chiamwongpaet, S., Kitisin, P., Natrujirote, P., Kittimunkong, S., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61127-7 · Cited by 1,463
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402269 · Cited by 1,296 · cited 3×
“Any serious adverse event 20 (10) 17 (8) 0.”
BackgroundGrant, R. M., Anderson, P. L., McMahan, V., Liu, A., Amico, K. R., Mehrotra, M., Hosek, S., Mosquera, C., Casapia, M., Montoya, O., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70847-3 · Cited by 1,208
Self-citationKamb, M. L., Fishbein, M., Douglas, Jr., Rhodes, F., Rogers, J., Bolan, G., Zenilman, J., Hoxworth, T., Malotte, C. K., Iatesta, M., et al. (1998) · JAMA · doi:10.1001/jama.280.13.1161 · Cited by 973 · cited 1×
“Immune from natural infection 18 (9) 31 (15)”
BackgroundEfficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
Hammer, S. M., Sobieszczyk, M. E., Janes, H., Karuna, S. T., Mulligan, M. J., Grove, D., Koblin, B. A., Buchbinder, S. P., Keefer, M. C., Tomaras, G. D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310566 · Cited by 598
García-Lerma, J. G., Otten, R. A., Qari, S. H., Jackson, E., Cong, M.-E., Masciotra, S., Luo, W., Kim, C., Adams, D. R., Monsour, M., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050028 · Cited by 350
The increase in global HIV epidemics in MSM
Beyrer, C., Sullivan, P., Sanchez, J., Baral, S. D., Collins, C., Wirtz, A. L., Altman, D., Trapence, G., & Mayer, K. (2013) · AIDS · doi:10.1097/01.aids.0000432449.30239.fe · Cited by 341
Population-based HIV-1 incidence in France, 2003–08: a modelling analysis
Le Vu, S., Le Strat, Y., Barin, F., Pillonel, J., Cazein, F., Bousquet, V., Brunet, S., Thierry, D., Semaille, C., Meyer, L., et al. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70167-5 · Cited by 179
Self-citationIntermittent Prophylaxis with Oral Truvada Protects Macaques from Rectal SHIV Infection
García-Lerma, J. G., Cong, M.-E., Mitchell, J., Youngpairoj, A. S., Zheng, Q., Masciotra, S., Martin, A., Kuklenyik, Z., Holder, A., Lipscomb, J., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000391 · Cited by 171
Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine?
Youle, M. S., & Wainberg, M. A. (2003) · AIDS · doi:10.1097/00002030-200304110-00027 · Cited by 44
Self-citationLavoie, É., Alary, M., Remis, R. S., Otis, J., Vincelette, J., Turmel, B., Lavoie, R., Mâsse, B. R., & LeClerc, R. (2008) · Sexually Transmitted Diseases · doi:10.1097/olq.0b013e31814fb113 · Cited by 28
Cited by
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Landovitz, R. J., Donnell, D., Clement, M. E., Hanscom, B., Cottle, L., Coelho, L., Cabello, R., Chariyalertsak, S., Dunne, E. F., Frank, I., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101016 · Cited by 900
Self-citationSexually transmitted infections: challenges ahead
Unemo, M., Bradshaw, C. S., Hocking, J. S., de Vries, H. J. C., Francis, S. C., Mabey, D., Marrazzo, J. M., Sonder, G. J. B., Schwebke, J. R., Hoornenborg, E., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30310-9 · Cited by 751
Saag, M. S., Benson, C. A., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Mugavero, M. J., Sax, P. E., Smith, D. M., Thompson, M. A., Buchbinder, S. P., et al. (2018) · JAMA · doi:10.1001/jama.2018.8431 · Cited by 698
Self-citationPeeling, R. W., Mabey, D., Kamb, M. L., Chen, X.-S., Radolf, J. D., & Benzaken, A. S. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.73 · Cited by 664
Günthard, H. F., Saag, M. S., Benson, C. A., del Rio, C., Eron, J. J., Gallant, J. E., Hoy, J. F., Mugavero, M. J., Sax, P. E., Thompson, M. A., et al. (2016) · JAMA · doi:10.1001/jama.2016.8900 · Cited by 656
Metadata
- Authors
- Molina, J.-M., Capitant, C., Spire, B., Pialoux, G., Cotte, L., Charreau, I., Tremblay, C., Le Gall, J.-M., Cua, E., Pasquet, A., Raffi, F., Pintado, C., Chidiac, C., Chas, J., Charbonneau, P., Delaugerre, C., Suzan-Monti, M., Loze, B., Fonsart, J., Peytavin, G., Cheret, A., Timsit, J., Girard, G., Lorente, N., Préau, M., Rooney, J. F., Wainberg, M. A., Thompson, D., Rozenbaum, W., Doré, V., Marchand, L., Simon, M.-C., Etien, N., Aboulker, J.-P., Meyer, L., & Delfraissy, J.-F.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-12-03
- Volume
- 373
- Issue
- 23
- Pages
- 2237-2246
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2319917590
- Cited by
- 1,633
- References
- 20
- FWCI
- 118.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.